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Increasing numbers of patients are receiving reduced intensity conditioning reg-imen allogeneic hematopoietic stem cell transplantation. We hypothesized thatthe use of bone marrow graft might decrease the risk of graft-versus-host disease
compared to peripheral blood after reduced intensity conditioning regimens with-
out compromising graft-versus-leukemia effects. Patients who underwent reduced
intensity conditioning regimen allogeneic hematopoietic stem cell transplantation
from 2000 to 2012 for acute leukemia, and who were reported to the Acute
Leukemia Working Party of the European Group for Blood and Marrow
Transplantation were included in the study. Eight hundred and thirty-seven
patients receiving bone marrow grafts were compared with 9011 peripheral blood
transplant recipients after reduced intensity conditioning regimen. Median follow
up of surviving patients was 27 months. Cumulative incidence of engraftment
(neutrophil ≥0.5x109/L at day 60) was lower in bone marrow recipients: 88% versus
95% (P<0.0001). Grade II to IV acute graft-versus-host disease was lower in bone
marrow recipients: 19% versus 24% for peripheral blood (P=0.005). In multivariate
analysis, after adjusting for differences between both groups, overall survival
[Hazard Ratio (HR) 0.90; P=0.05] and leukemia-free survival (HR 0.88; P=0.01)
were higher in patients transplanted with peripheral blood compared to bone mar-
row grafts. Furthermore, peripheral blood graft was also associated with decreased
risk of relapse (HR 0.78; P=0.0001). There was no significant difference in non-
relapse mortality between recipients of bone marrow and peripheral blood grafts,
and chronic graft-versus-host disease was significantly higher after peripheral blood
grafts (HR 1.38; P<0.0001).  Despite the limitation of a retrospective registry-based
study, we found that peripheral blood grafts after reduced intensity conditioning
regimens had better overall and leukemia-free survival than bone marrow grafts.
However, there is an increase in chronic graft-versus-host disease after peripheral
blood grafts. Long-term follow up is needed to clarify whether chronic graft-versus-
host disease might increase the risk of late morbidity and mortality.
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Introduction
Indications for allogeneic hematopoietic stem cell trans-
plantation (HCT) have changed in the past decade. The
most common indication for HCT in 2013 was acute
myeloid leukemia (AML), and currently nearly 50% of
HCTs are being carried out for acute leukemia including
AML and acute lymphoid leukemia (ALL).1,2 Furthermore,
following the introduction of reduced intensity condition-
ing (RIC) regimens, individuals with co-morbidities and
those 65 years of age and older are now eligible to under-
go HCT.3-5 
The use of peripheral blood stem cells (PB) has largely
replaced bone marrow (BM) as the main stem cell source
for HCT in adults with hematologic malignancies.1
However, limited data are available on the impact of the
stem cell source (related or unrelated donor) in the setting
of RIC HCT,6-10 including our small previous European
Group for Blood and Marrow Transplantation (EBMT)
series.9,10 In 8 of 9 published comparative randomized
studies, all participants received a myeloablative HCT,
using different regimens depending on the underlying dis-
ease.6 Only one randomized study by Anasetti et al.7
included RIC regimens in the comparative analysis of
BMT versus PBSCT for a variety of hematologic malignan-
cies. Participants predominantly received a myeloablative
HCT, with only 20% of the BMT group receiving RIC,
and very few were performed for acute leukemia. A study
recently published by the Center for International Blood
and Marrow Transplant Research (CIBMTR) reported
comparative analysis of BMT versus PBSCT after RIC reg-
imen.8 Similar to the report by Anasetti et al.,7 the study
population included a variety of hematologic malignancies
and the analysis included only 108 with AML patients in
the BMT RIC group. Outcomes for unrelated donor allo-
grafting have improved over time. This is probably due to
improved high-resolution HLA-typing and better match-
ing, and the availability of intensive supportive care.11,12
Moreover, outcomes for unrelated donor HCT after RIC
regimens appear comparable to those seen with sibling
donor RIC HCT.3,13-15 Here we report on transplant out-
comes after related or unrelated donor BMT (n=837) versus
PBSCT (n=9011) in the setting of reduced intensity condi-
tioning for the treatment of adults with acute leukemia
using data reported to the ALWP of the EBMT from 2000
to 2012.
Methods
Study design and data collection
This was a retrospective multicenter registry analysis. Data
were provided and approved for this study by the Acute Leukemia
Working Party (ALWP) of the EBMT group registry. The EBMT is
a non-profit, scientific society representing more than 600 trans-
plant centers, mainly in Europe. The EBMT promotes all initiatives
that aim to improve stem cell transplantation or cellular therapy,
which includes registering all activities relating to stem cell trans-
plants. Data are entered, managed, and maintained in a central
database that includes all EBMT centers. There are no restrictions
regarding centers that can report data except those legal require-
ments concerning patient consent, data confidentiality and accura-
cy.  Quality control measures include several independent sys-
tems: confirmation of validity of the entered data by the reporting
team, selective comparison of the survey data with MED-A data
sets in the EBMT registry database, cross-checking with the
national registries, and regular in-house and external data audits.
Since 1990, patients have provided informed consent authorizing
the use of their personal information for research purposes.
Eligibility criteria for this analysis included adult patients (age >18
years) with acute leukemia receiving HLA-matched or mis-
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Table 1. Patients’ disease and transplant characteristics.
Patients BMT PBSCT P
N. of patients 837 9011
Recipient age at SCT, median 54 (18-77) 57 (18-77) <0.0001
(range)(years)
Recipient gender, n (%) 0.33
Male 459 (55%) 4790 (53%)
Female 376 (45%) 4214 (47%)
Missing 2 7
Diagnosis
AML 702 (84%) 8075 (90%)
ALL 135 (16%) 936 (10%)
Median follow up (alive patients), 29 27 0.27
months (IQR) (12-56) (11-54)
Donor age (years, range) 43 (9-74) 47 (13-80) 0.005
Donor gender, n (%) 0.42
Male 487 (59%) 5401 (61%)
Female 338 (41%) 3531 (39%)
Missing 12 79
Female donor to male recipient, 181 1733 0.08
n (%) (22%) (19%)
Disease status at HCT, n (%) 0.002@
CR1 475 (57%) 5193 (57%)
≥CR2   177 (21%) 1513 (17%)
Active disease 185 (22%) 2305 (26%)
Karnofsky at HCT, <90%, n (%) 215 (37%) 2226 (31%) 0.006
Recipient positive CMV serology 508 (69%) 5682 (67%) 0.26
Donor positive CMV serology 403 (54%) 4526 (53%) 0.69
Human leukocyte antigen matching <0.0001
HLA-identical sibling 388 (46%) 4751 (53%)
URD (10/10 match) 220 (26%) 2894 (32%)
1- locus mismatched-URD (9/10) 107 (13%) 950 (10%)
Mismatched-related donor 122 (15%) 416 (5%)
Conditioning regimen
Bu-Flu 314 3240
Low-dose TBI 210 2730
Flu-Mel 149 1845
Treo-Bu 30 307
Cy-Thiotepa 66 155
Flu-Cy 29 384
Other 39 350
In vivo T-cell depletion, n (%) 394 (48%) 5246 (61%) <0.0001
Anti-thymocyte globulin 296 3808
Anti-lymphocyte globulin 29 215
Alemtuzumab 69 1223
GvHD prophylaxis 0.38
Calcineurin inhibitors and either 814 8471
MTX or MMF or both
Tacrolimus and sirolimus 5 62
Other + missing 18 478
BMT: bone marrow transplantation; PBSCT: peripheral blood stem cell transplantation;
AML: acute myeloid leukemia; CMV: cytomegalovirus; HCT: stem cell transplantation;
Bu: busulfan; Cy: cyclophosphamide; Flu: fludarabine; Mel: melphalan; TBI: total body
irradiation; MTX: methotrexate; Treo: treosulfan; @active disease versus complete
remission (CR); P=0.03. 
matched related or unrelated donor BM or PB transplants after RIC
regimens from 2000 to 2012.  Two hundred and ninety-four trans-
plant centers reported data on recipients of BM and PB grafts after
related or unrelated donor transplantation. We do not have any
information about why patients were allocated to a specific graft
(BM vs. PB) in the registry, and it is difficult to distinguish between
the role of the conditioning approach adopted and the role of a
potential effect of the individual center (“center effect”); however,
a center effect was not evident in the analysis. All unrelated donors
were HLA (-A, -B, -C, DRB1, -DQB1) matched (10/10) or mis-
matched at one loci. Exclusion criteria included previous allogeneic
or cord blood transplantation, and recipients of grafts that were
either ex vivoT-cell depleted or CD34 selected. Data were collected
on recipient and donor characteristics [age, gender,
cytomegalovirus (CMV) serostatus], disease status at transplant,
transplant-related factors including conditioning regimen,
immunosuppression (in vivo T-cell depletion vs. none), stem cell
source (BM or PB), graft-versus-host disease (GvHD) prophylaxis,
and outcome variables [acute and chronic GvHD,16,17 relapse, non-
relapse mortality (NRM), leukemia-free survival (LFS), overall sur-
vival (OS), and causes of death]. Regimens were classified as RIC
based on published criteria.18
Statistical analysis 
The primary end points of the study were OS and LFS.
Secondary end points included relapse incidence (RI), NRM,
engraftment, incidence and severity of acute and chronic GvHD.
The starting point for time-to-event analysis was date of trans-
plantation. OS was defined as the time to death from any cause.
Surviving patients were censored at time of last follow up. LFS
was defined as survival without relapse or progression. Patients
surviving in continuous CR were censored at the time of last fol-
low up. RI was defined as time to onset of leukemia recurrence.
NRM was the competing risk, and patients surviving in continu-
ous complete remission were censored at last contact. NRM was
defined as death without relapse/progression (relapse was the
competing risk). The two groups were compared according to the
stem cell sources (BM vs. PB) using the χ2 test for qualitative vari-
ables, whereas the Mann-Whitney test was applied for continuous
parameters. Univariate comparisons were made using the log rank
test for OS, LFS, and the Gray test for RI, NRM and GvHD cumu-
lative incidences. Multivariate analyses were performed using
logistic regression for acute GvHD and Cox proportional hazards
model for all other end points (variables tested are provided in
Table 1). All factors known as potentially related to the outcome
were included in the final model. First-order interactions between
the main effect and the other variables were tested in multivariate
models. All tests were two-sided. The type I error rate was fixed
at 0.05 for determination of factors associated with time to event
outcomes. Statistical analyses were performed with SPSS 22.0
(IBM Corp., Armonk, NY, USA) and R 3.1.1 software packages (R
Development Core Team, Vienna, Austria).
Results
Patients’, disease and transplant characteristics
Details of patients’, disease and transplant characteris-
tics are summarized in Table 1. 
A total of 9848 patients with AL were included in the
study: 837 patients received BM and 9011 PB transplants
performed between 2000 and 2012; 8777 (89.1%) patients
had AML (BM=702, PB=8075) and 1071 (10.9%) ALL
(BM=135, PB=936). PBSCT recipients were older with a
median age of 57 years (range 18-77) in comparison to 54
years (range 18-77) for the BM group (P<0.0001). Median
follow up of surviving patients in the BM group was 29
(IQR, 12-56) months, while that of the PB group was 27
(IQR, 11-54) months (P=0.27). Significantly higher num-
bers of patients had Karnofsky Performance Status (KPS)
score less than 90% (37 vs. 31%; P=0.006) in the BM
group. There were more patients with advanced disease in
PB compared to the BM group (26 vs. 22%; P=0.002).
There were no statistically significant differences in cyto-
genetic risk categories in AML or ALL groups between
patients receiving BM or PB transplantations. The propor-
tion of CMV seropositive recipients and donors were
comparable in the BM and PB groups [69% vs. 67%
(P=0.26) and 54% vs. 53% (P=0.69), respectively]. 
Details of transplant characteristics and conditioning
regimen are summarized in Table 1. The majority of
patients received chemotherapy-based RIC regimens
(BM=75%, PB=70%; P=0.002).  Among the BM recipients,
388 (46%) received a graft from HLA-identical sibling
donor, 220 (26%) matched unrelated donor (MUD)
(10/10), 107 (13%) mismatched unrelated donor (MM-
URD) (9/10), and 122 (15%) received mismatched-related
donor HCT; corresponding numbers in the PB cohort were
4751 (53%), 2894 (32%), 950 (10%), and 416 (5%), respec-
tively. The percentage of patients receiving in vivo T-cell
depletion was higher in the PB group (61% vs. 48% in BM;
P<0.0001). Patients receiving ex vivo T-cell depletion were
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Table 2. Multivariate analysis adjusted outcomes after transplantation
by graft source (peripheral blood vs. bone marrow).
Outcome variable                               HR (95% CI)                      P
Overall survival                                       0.90 (0.81-1.00)                      0.05
Leukemia-free survival                         0.88 (0.79-0.97)                      0.01
Relapse                                                     0.78 (0.69-0.88)                    0.0001
Non-relapse mortality                           1.09 (0.91-1.31)                      0.34
Acute GvHD (grade II-IV)*                  1.31 (1.07-1.60)                     0.008
Chronic GvHD                                         1.38 (1.17-1.60)                    0.0001
GvHD: graft-versus-host disease; *OR: odds ratio.
Table 3. The 2-year adjusted probabilities of transplant outcome after bone marrow versus peripheral blood grafts.
RI NRM LFS OS cGvHD
BM 43% (39-47) 18% (16-21) 39% (35-42) 47% (44-51) 29% (26-32)
PB 35% (34-37) 20% (18-23) 44% (43-45) 50% (49-52) 36% (35-37)
P 0.0004 0.19 0.009 0.05 0.0003
BM: bone marrow; PB: peripheral blood; RI: relapse incidence; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; cGvHD: chronic graft-versus-host dis-
ease; BM: bone marrow; PB: peripheral blood.
excluded from the analysis. The choice of conditioning,
graft source and GvHD prophylaxis was dependent on the
protocols of the individual centers and the strategies
adopted for transplantation.
Engraftment and graft-versus-host disease
Median time to neutrophil recovery (PMN ≥0.5x109/L)
was 20 days and 16 days after BM and PB HCT, respec-
tively (P<0.0001). The corresponding day 60 probability of
neutrophil recovery (PMN ≥0.5x109/L at day 60) was 88%
(95%CI: 86-90) after BM versus 95% (95%CI: 95-96) in the
PB group (P<0.0001). 
The rates of day 100 grade II-IV acute GvHD were 24%
versus 19% (P=0.005) and 10% versus 6% (P=0.003) for
grade III-IV GvHD in PB compared with BM transplant
recipients. 
In multivariate analysis, the factors associated with
increased risk of grade II-IV acute GvHD were PB versus
BM (OR 1.31; 95%CI: 1.07-1.60; P=0.008; Table 2), active
disease (OR 1.33; 95%CI: 1.18-1.51; P<0.0001), poor cyto-
genetic risk group (OR 1.30; 95%CI: 1.10-1.53; P=0.002),
CMV donor seropositivity (OR 1.12; 95%CI: 1.01-1.25;
P=0.05), female donor for male recipients (OR 1.19;
95%CI: 1.04-1.35; P=0.01), MUD (10/10) and MM-URD
(9/10) allo-SCT compared with HLA-identical donor [OR
1.78; 95%CI: 1.57-2.02 (P<0.0001) and OR 2.30; 95%CI:
1.95-2.71 (P<0.0001), respectively], and absence of in vivo
T-depletion (OR 1.46; 95%CI: 1.30-1.64; P<0.0001).
The 2-year incidence of chronic GvHD was higher after
PB grafts [36% (95%CI: 35-37) vs. 29% (95%CI: 26-32) in
the BM group; P=0.0003] (Table 3 and Figure 1). The sever-
ity of chronic GvHD was graded as extensive in 1287
(16.6%) of PBSCT recipients compared with 69 (9.3%) in
the BMT group (P<0.0001). Similarly, the GvHD-related
mortality was higher after PBSCT compared to BMT
(13% vs. 7.4%; P=0.001).   
In multivariate analysis, chronic GvHD was significant-
ly higher after PB grafts (HR 1.38; 95%CI: 1.17-1.60;
P<0.0001) (Table 2). Other factors determining the risk of
cGvHD that were independent of graft source included
active disease at transplant (HR 1.20, 95%CI: 1.09-1.34;
P=0.0004), older age at allo-SCT (HR 1.02, 95%CI: 1.00-
1.03; P=0.03), female donor for male recipients (HR 1.18,
95%CI: 1.08-1.30; P=0.0004), MUD (10/10) and MM-
URD (9/10) allo-SCT compared with HLA-identical donor
(HR 1.12, 95%CI: 1.02-1.23; P=0.02, and HR 1.23, 95%CI:
1.07-1.41; P=0.003, respectively). There was no significant
difference in risk of chronic GvHD between HLA-identical
and related mismatched donors (HR 0.94, 95%CI: 0.76-
1.15; P=0.54). In vivo T-cell depletion was associated with
lower risk of chronic GvHD (HR 0.57, 95%CI: 0.53-0.63;
P<0.0001) independent of graft type. 
BMT or PBSCT after RIC regimen for acute leukemia 
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Figure 1. Long-term outcomes after transplantation
by graft type. (A) RI: relapse incidence. (B) NRM: non-
relapse mortality. (C) LFS: leukemia-free survival. (D)
OS: overall survival. (E) cGvHD: chronic graft-versus-
host disease. 
A B C
D E
Non-relapse mortality
There was no significant difference in 2-year NRM
between the BM and PB groups in univariate analysis
(18%, 95%CI: 16-21 after BM versus 20%, 95%CI: 18-23
after PB grafts; P=0.19) (Table 3 and Figure 1). 
In multivariate analysis, there was no significant differ-
ence in NRM between BM and PB grafts (HR 1.09, 95%CI:
0.91-1.31; P=0.34) (Table 2). Other factors associated with
higher NRM independent of graft source were CR2 versus
CR1 (HR 1.27, 95%CI: 1.11-1.45; P=0.0004), active dis-
ease (HR 1.85, 95%CI: 1.65-2.07; P<0.0001), secondary
AML (HR 1.32, 95%CI: 1.17-1.48), older age at HCT (HR
1.08, 95%CI: 1.06-1.10; P<0.0001), CMV seropositive
recipients (HR 1.34, 95%CI: 1.20-1.50; P<0.0001), CMV
seropositive donors (HR 1.13, 95%CI: 1.02-1.25; P=0.02),
female donor for a male recipient (HR 1.21, 95%CI: 1.07-
1.36; P=0.002), matched-URD (10/10), MM-URD (9/10)
and related mismatched donors compared with HLA-
identical donor [HR 1.60, 95%CI: 1.42-1.80 (P<0.0001);
HR 2.11, 95%CI: 1.81-2.45 (P<0.0001), and HR 2.34
95%CI: 1.94-2.83 (P<0.0001),  respectively]. In vivo T-cell
depletion was associated with lower NRM (HR 0.79,
95%CI: 0.71-0.87; P<0.0001) independent of graft type.
Relapse
Two-year RI was lower after PB (35%, 95%CI: 34-37)
compared to BM transplants (43%, 95%CI: 39-47)
(P=0.0004) (Table 3 and Figure 1). 
In multivariate analysis, RI was significantly lower after
PB grafts (HR 0.78, 95%CI: 0.69-0.88; P=0.0001) (Table 2).
Factors associated with higher RI independent of graft
source were: diagnosis of ALL versus AML (HR 1.38,
95%CI: 1.23-1.55; P<0.0001), CR2 versus CR1 (HR 1.26,
95%CI: 1.13-1.39), active disease (HR 2.45, 95%CI: 2.26-
2.66; P<0.0001), poor cytogenetic risk group (HR 1.51,
95%CI: 1.36-1.68; P<0.0001), in vivo T-cell depletion (HR
1.10, 95% CI, 1.01-1.19; P=0.02), and low-dose total body
irradiation (TBI)-based RIC regimens compared to
chemotherapy-based regimens (fludarabine combined
with busulfan or melphalan) (HR 1.12, 95%CI: 1.03-1.21;
P=0.01). Relapse risk was lower for patients receiving
MUD (10/10) or MM-URD (9/10) compared with an HLA-
identical donor [HR 0.77, 95%CI: 0.71-0.85 (P<0.0001)
and HR 0.82, 95%CI: 0.73-0.93 (P=0.002), respectively].
Leukemia-free survival
Two-year LFS was higher after PB (44%, 95%CI: 43-45)
compared with BM transplants (39%, 95%CI: 35-42)
(P=0.009) (Table 3 and Figure 1). 
In multivariate analysis, the only factor associated with
superior LFS was the use of PB grafts (HR 0.88, 95%CI:
0.79-0.97; P=0.01) (Table 2). 
Factors associated with inferior LFS independent of graft
source were diagnosis of ALL versus AML (HR 1.42,
95%CI: 1.29-1.57; P<0.0001), CR2 versus CR1 (HR 1.26,
95%CI: 1.16-1.37), active disease (HR 2.22, 95%CI: 2.07-
2.37; P<0.0001), poor cytogenetic risk group (HR 1.35,
95%CI: 1.23-1.47; P<0.0001), secondary AML (HR 1.16,
95%CI: 1.08-1.25), older age at HCT (HR 1.03, 95%CI:
1.02-1.04; P<0.0001), CMV-positive recipients (HR 1.07,
95%CI: 1.00-1.14; P=0.04), MM-URD (9/10) or mis-
matched-related donor compared with HLA-identical
donor [HR 1.16, 95%CI: 1.05-1.27 (P=0.003) and HR 1.26,
95%CI: 1.12-1.43 (P=0.0002), respectively] and low-dose
TBI-based RIC regimens compared with chemotherapy-
based regimens (fludarabine combined with busulfan or
melphalan) (HR 1.08, 95%CI: 1.01-1.15; P=0.02). 
Overall survival
Two-year OS was higher after PB grafts (50%, 95%CI:
49-52) compared with BM transplants (47%, 95%CI: 44-
51) (P=0.05) (Table 3 and Figure 1). In multivariate analy-
sis, factors associated with superior OS were PB grafts (HR
0.90, 95%CI: 0.81-1.00; P=0.05) (Table 2) and in vivo T-cell
depletion (HR 0.93, 95%CI: 0.87-1.00; P=0.04). 
Factors associated with inferior OS independent of graft
source included a diagnosis of ALL versus AML (HR 1.42,
95%CI: 1.28-1.57; P<0.0001), CR2 versus CR1 (HR 1.28,
95%CI: 1.17-1.39; P<0.0001), active disease at transplant
(HR 2.21, 95%CI: 2.06-2.37; P<0.0001), poor cytogenetic
risk group (HR 1.27, 95%CI: 1.15-1.39; P<0.0001), second-
ary AML (HR 1.17, 95%CI: 1.08-1.26; P=0.0001), older age
at HCT (by 10 years) (HR 1.04, 95%CI: 1.03-1.06;
P<0.0001), CMV-positive recipients (HR 1.12, 95%CI:
1.05-1.20; P=0.0001), female donor for male recipients
(HR 1.09, 95%CI: 1.01-1.18; P=0.02),  MUD  (10/10), MM-
URD (9/10) donors and MM-related donor compared with
HLA-identical donor [HR 1.09, 95%CI: 1.01-1.18 (P=0.02),
HR 1.31, 95%CI: 1.18-1.45 (P<0.0001) and HR 1.44,
95%CI: 1.27-1.64 (P<0.0001), respectively] and low-dose
TBI-based RIC regimens compared chemotherapy-based
regimens (fludarabine combined with busulfan or melpha-
lan) (HR 1.08, 95%CI: 1.01-1.16; P=0.03).
Impact of graft source on other variables
The primary purpose of our analysis was to explore out-
come differences between BM and PB transplantation in
patients with acute leukemia after RIC regimens. The
effect of stem cell source (BM vs. PB) on survival was inde-
pendent of disease (interaction test P=0.22). There was no
significant interaction between the graft source and dis-
ease status at transplant (interaction test P=0.57). Results
were similar among HLA-mismatched pairs and recipients
with active disease, although this study was not designed
to detect potential differences within these subsets.
Discussion
This large, multicenter, registry study shows that the
use of PB grafts after RIC gives superior outcome in
patients with acute leukemia. Moreover, PBSCT recipients
had a lower risk of relapse, most probably due to a
stronger graft-versus-leukemia (GvL) effect not just in
patients in CR, but, more importantly, in patients with
active disease pre-HCT. This finding is of major clinical
significance as an increasing number of patients are under-
going RIC HCT for acute leukemia, a significant number
of whom receive BM grafts;1 indeed, 8.5% (n=837) of 9848
patients transplanted from 2000 to 2012 at centers report-
ing to the EBMT received BM grafts. However, the
increased risk of chronic GvHD observed in our series
after PB grafts is alarming, and long-term follow up is
awaited to clarify if excess risk of chronic GvHD among
RIC PBSCT recipients translates into continued GvL effect
or increased late morbidity and mortality.19
We investigated patient, disease, and transplantation
factors affecting survival, LFS, relapse, NRM and GvHD in
a well-characterized population of nearly 10,000 adult
acute leukemia patients receiving either BMT or PBSCT.
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Overall, nearly 50% of patients (Figure 1) transplanted
after RIC HCT survived beyond two years, with higher
survival for AML compared to ALL. Notably, the low-dose
TBI-based regimen had inferior outcome (for both patients
in CR1 and active diseases) compared to chemotherapy-
based RIC regimens. Results were similar among related
or unrelated donor groups. 
Patients receiving in vivo T-cell depletion (either ATG or
alemtuzumab) had a significantly lower risk of chronic
GvHD and higher OS despite their higher relapse rate,
which was offset by lower NRM. Anti-thymocyte globu-
lin or alemtuzumab with standard GvHD prophylaxis
(which has been shown to be effective in lowering GvHD
rates as well as its severity) was used for 48% of BM and
61% of PB transplantations in our series. This study was
not designed to analyze separately patients receiving low-
dose ATG/alemtuzumab, which is commonly used today;
however, previous studies have shown that low-dose
ATG/alemtuzumab reduced the risk of chronic GvHD and
NRM without compromising the GvL effect.20-25  
Previous smaller studies demonstrated the non-inferior-
ity of RIC PBSCT compared to RIC BMT for patients with
acute leukemia.7-10 Our results differ from the findings in
published studies comparing RIC outcomes with BM with
PB grafts. This discrepancy may be due to differences in
the study populations. Firstly, the improved survival,
decreased relapse risk and higher rates of grade II to IV
acute GvHD (also grade III-IV) after transplants with PB
compared with BM grafts are in contrast to previous
reports.6,8,26 The survival rates in the BM and PB groups in
our study are comparable to a study from the CIBMTR by
Eapen et al.,8 reporting a 3%-5% difference in OS and LFS
between the two groups, which was not statistically sig-
nificant. In our analysis, results were statistically signifi-
cant, and this may reflect the difference in power between
the two studies.  Secondly, the cumulative incidence of
engraftment and the risk of chronic GvHD were higher
after PBSCT compared with BMT, in keeping with other
reports.6,7,27,28 
Chronic GvHD can impair quality of life and is associat-
ed with significant morbidity and mortality among HCT
recipients. However, the costs involved, the economic bur-
den and the use of resources to manage long-term compli-
cations associated with cGvHD have not been well
described.  Studies of transplantation costs are complex
and difficult to conduct because of the wide variation in
transplant methods, conditioning approaches, GvHD pro-
phylaxis regimens and supportive care practices. More
research is needed to better understand the costs of
cGvHD to patients, centers and the health care system,
and to determine whether the lower incidence and sever-
ity of cGvHD with BM grafts leads to long-term savings of
resources compared to PB grafts. Also, trials aimed at bet-
ter GvHD prophylaxis that is either drug-mediated or
through graft manipulation are needed to reduce chronic
GvHD rates after RIC PBSCT. 
We acknowledge that there are differences in patients’,
disease, and transplantation characteristics between those
who received BMT and PBSCT. We have addressed this
by performing a carefully controlled well-adjusted analysis
that considered patients', disease, and transplantation
characteristics as well as any transplantation center effects
in this multicenter registry analysis. In addition, there may
be unmeasured and unknown factors that have not been
considered, which is an inherent limitation of this type of
analysis.  However, we believe that the results of this
analysis are very important in the absence of available
prospective data. 
Only through the conduct of well-designed clinical trials
will we be able to understand and appreciate the complex-
ities of stem cell source choices and their outcome after
RIC HCT. Unfortunately, there are no ongoing trials to
compare outcomes after BMT with that after PBSCT fol-
lowing an RIC regimen for acute leukemia. Therefore, in
the absence of any prospect of such comparative studies,
our data support the use of PB (related or unrelated donor)
grafts after RIC for adult patients with acute leukemia in
remission or with advanced disease. 
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